# Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

> **NCT01122121** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 273 (actual)

## Conditions studied

- Prostatic Neoplasms, Locally Advanced

## Interventions

- **DRUG:** Leuprorelin SR
- **RADIATION:** Radiotherapy
- **DRUG:** Flutamide

## Key facts

- **NCT ID:** NCT01122121
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2008-12
- **Final completion:** 2009-06
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2015-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122121, "Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01122121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*